Abstract: An aminoglycoside compound represented by the following formula (I) ##STR1## wherein one of R.sub.1 and R.sub.2 represents a hydrogen atom, and the other represents a methyl group,R.sub.3 represents a hydrogen atom or a hydroxyl group,R.sub.4 represents a hydrogen atom, a hydroxyl group or a methoxy group,n represents an integer of 1 to 5,W represents a divalent group of the formula --NHCO.fwdarw., --CONH.fwdarw., --COO.fwdarw., or --S.fwdarw. in which .fwdarw. represents a bond to X, andX represents (i) a single bond or (ii) a C.sub.1 -C.sub.20 trivalent acyclic saturated hydrocarbon group, andY and Z are separately defined according to the cases (i) and (ii) above, and its pharmaceutically acceptable acid addition salt; and a process for producing the above aminoglycoside compound. A pharmaceutical composition comprising the above aminoglycoside compound is useful as an antibiotic.

Abstract: An aminoglycoside compound represented by the following formula (1) ##STR1## wherein R.sub.1 and R.sub.2 are different from each other and each represents a hydrogen atom or a methyl group,R.sub.3 represents a hydrogen atom, a hydroxyl group or a methoxy group,A represents a residue of a C.sub.2 -C.sub.11 amino acid or a residue of a dipeptide composed of two said amino acids which are identical or different, and n represents 1 or 2;and its acid addition salt; and a process for the production thereof.

Abstract: A novel antibiotic designated as KA-6643 and having the formula, ##STR1## wherein R is hydrogen or --SO.sub.3 H.

Abstract: A process for producing an antibiotic, which comprises cultivating an antibiotic KA-6606-producing strain of the genus Saccharopolyspora in a nutrient culture medium, isolating an antibiotic KA-6606-containing substance from the culture broth, and separating from the resulting antibiotic KA-6606-containing substance at least one antibiotic selected from the group consisting of antibiotic KA-6606 VII, KA-6606 VIII, KA-6606 IX, KA-6606 X, KA-6606 XI, KA-6606 XII, KA-6606 XIII, KA-6606 XIV, KA-6606 XV, KA-6606 XVI and KA-6606 XVII; and novel antibiotics KA-6606 XII, XIII and XV to XVII.

Abstract: A plasminogen activator obtained from a tissue cultured liquor of human normal tissue derived cells, e.g., human embryonic derived cells, human placenta derived cells etc., and having the following properties:(a) molecular weight measured by gel filtration: 63,000.+-.10,000,(b) isoelectric point: 7.0-8.5,(c) affinity to fibrin: present,(d) affinity to concanavalin A: present,(e) optimum pH: 7-9.5, and(f) stability: does not lose activity at 60.degree. C. for 10 hours but loses about 5% of activity at pH 2-3 at 98.degree. C. for a minute; a process for the production of the aforesaid plasminogen activator; and a thrombolytic composition containing the aforesaid plasminogen activator as an active ingredient are disclosed.

Abstract: A compound of the following formula ##STR1## wherein each of R.sub.1, R.sub.2 and R.sub.3 represents H or CH.sub.3, R.sub.4 represents H or C.sub.2 -C.sub.4 acyl substituted at the 2-, 3- or 4-position by an amino group, and Y represents ##STR2## provided that R.sub.1 and R.sub.2 are not CH.sub.3 at the same time, and an acid addition salt thereof; and a process for the production thereof.

Abstract: An aminoglycoside represented by the following formula (1) ##STR1## wherein each of R.sub.1 and R.sub.2 represents a hydrogen atom or a methyl group, R.sub.3 represents a hydrogen atom or an aminoacyl group, R.sub.4 represents a hydrogen atom or a hydroxyl or methoxy group, and R.sub.5 represents a hydrogen atom or a hydroxyl group, or a pharmaceutically acceptable acid addition salt thereof, a process for the production thereof and a pharmaceutical use thereof.

Abstract: A-KA-6643-series antibiotic comprising at least one substance represented by any of the following formulae, or a salt or ester thereof: ##STR1## is effectively useful as an antibacterial and .beta.-lactamase inhibiting agent.

Abstract: An aminoglycoside compound of the following formula ##STR1## wherein one of R.sub.1 and R.sub.2 represents a hydrogen atom and the other, a methyl group, R.sub.3 represents a hydrogen atom or an amino acyl group having 2 to 5 carbon atoms, R.sub.4 represents a lower alkyl group substituted by one or two substituents selected from the class consisting of hydroxy and amino groups, or a hexopyranosyl group whose hydroxy groups may be substituted by amino groups,and a pharmaceutically acceptable acid addition salt thereof; and an antibiotic composition comprising said compound and its pharmaceutically acceptable acid addition salt.

Abstract: A process for producing an antibiotic, which comprises cultivating an antibiotic KA-6606-producing strain of an genus Saccharopolyspora in a nutrient culture medium, isolating the antibiotic KA-6606-containing substance from the culture broth, and separating from the resulting antibiotic KA-6606-containing substance at least one antibiotic selected from the group consisting of antibiotic KA-6606 VII, KA-6606 VIII, KA-6606 IX, KIA-6606 X, KA-6606 XI, KA-6606 XII, KA-6606 XIII, KA-6606 XIV, KA-6606 XV, KIA-6606 XVI and KA-6606 XVII; and novel antibiotics KA-6606 XII, XIII and XV to XVII.

Abstract: An antibiotic KA-6643-A or a salt thereof having the formula: ##STR1## is produced by a process comprising the step of hydrolyzing an antibiotic KA-6643-B of the formula: ##STR2##

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO;process for preparation thereof; and biologically pure culture for use therein.

Abstract: A compound of the general formula: ##STR1## wherein R.sub.1 and R.sub.2 are different and each represents a hydrogen atom or a methyl group, R.sub.3 represents a hydrogen atom, or a glycyl group which may be substituted, and the symbol between the carbon atoms at the 5- and 6- positions represents a single or double bond, and an acid addition salt thereof; and its antibiotic use.

Abstract: An antibiotic substance KA-7038 selected from the group consisting of the compounds having formulae I to VII described in claim 1, mixtures thereof and acid addition salts thereof; an antibiotic composition composed of (i) antibiotically effective amount of aforesaid antibiotic substance KA-7038, and (ii) a pharmaceutically acceptable diluent or carrier. The antibiotic substance KA-7038 can be produced by cultivating an antibiotic substance KA-7038-producing strain belonging to genus Streptomyces, for example Streptomyces sp. KC-7038, and isolating the antibiotic substance KA-7038 from the culture broth.

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO; process for preparation thereof; and biologically pure culture for use therein.

Abstract: An antibiotic substance KA-7038 selected from the group consisting of the compounds having formulae I to VII described in claim 1, mixtures thereof and acid addition salts thereof; an antibiotic composition composed of (i) antibiotically effective amount of aforesaid antibiotic substance KA-7038, and (ii) a pharmaceutically acceptable diluent or carrier. The antibiotic substance KA-7038 can be produced by cultivating an antibiotic substance KA-7038-producing strain belonging to genus Streptomyces, for example Streptomyces sp. KC-7038, and isolating the antibiotic substance KA-7038 from the culture broth.

Abstract: The specification describes an economical process for the preparation of immunoglobulin for intravenous administration. An immunoglobulin can be, in accordance with the process, purified by a combination of a fractional precipitation method and an affinity chromatography. As a precipitant, divalent or trivalent metal salts are used and a complex of human IgG and a polyhydroxy polymeric compound is employed as an adsorbent. Purified immunoglobulin contains little or no aggregated or partially denatured globulin which is believed to cause anaphylaxis when administered intravenously. Prior art techniques cannot economically provide immunoglobulin in such a purified form and only intramuscular injections were feasible. Intravenous administrations allow immunoglobulin to be dosed in a larger amount and to act much faster than intramuscular injections.

Abstract: Novel aminoglycosides of the following formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different and each represents a hydrogen atom or a methyl group, R.sub.3 represents a hydrogen atom or an optionally substituted aminoacyl group having 2 to 4 carbon atoms in the acyl moiety, and when all of R.sub.1, R.sub.2 and R.sub.3 are hydrogen atoms, the methylamino group at the 4-position is not oriented trans to the hydroxyl groups at the 3- and 5-positions; and acid addition salts thereof, which are useful as antibiotics; and process for producing compounds containing the same.

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO;process for preparation thereof; and biologically pure culture for use therein.